Status and related factors of postoperative recurrence of ovarian endometriosis: a cross-sectional study of 874 cases

Yang, Xin-Chun; Bao, Meiru; Tian, Haijun; Sun, Weiwei; Liu, Yong; Yang, Yanhuan; Yu, You; Zhao, Ting; Xu, Ran; Hou, Ruijie; Zhao, Ren

doi:10.1007/s00404-023-06932-x

Cited by 3 publications

(2 citation statements)

References 34 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although much of the literature infers a benefit to the postoperative use of hormonal treatment in reducing endometriosis recurrence, two studies failed to demonstrate a benefit [32,33].…”

Section: Postoperative Hormone Use For Recurrence Of Diseasementioning

confidence: 99%

Perioperative hormone treatment of endometriosis

Farkas,

Lazaridis,

Odejinmi

et al. 2023

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of review The use of hormonally suppressive medication to reduce levels of reproductive hormones around the time of surgery is widely used in the management of endometriosis. This review summarizes the current evidence concerning the perioperative use of hormonal treatment in the management of endometriosis. Recent findings European Society of Human Reproduction and Embryology (ESHRE) guidance Surgical Outcomes and Complications of Laparoscopic Hysterectomy for Endometriosis: A Multicentre Cohort Study Pre and postsurgical medical therapy for endometriosis surgery. Cochrane 2020 Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. BJOG 2021 Summary The literature highlights the importance of hormonal treatment for symptom relief, reduced surgical complications and postoperative benefits, including a reduction in pain, disease recurrence and improved pregnancy rates. The treatment of endometriosis can be broadly categorized into medical, commonly using hormonal suppression medications and surgical, in which endometriosis tissue is excised or ablated. This review aims to outline current management strategies and examines the relationship between the two treatment modalities.

show abstract

“…Although much of the literature infers a benefit to the postoperative use of hormonal treatment in reducing endometriosis recurrence, two studies failed to demonstrate a benefit [32,33].…”

Section: Postoperative Hormone Use For Recurrence Of Diseasementioning

confidence: 99%

Perioperative hormone treatment of endometriosis

Farkas,

Lazaridis,

Odejinmi

et al. 2023

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…Согласно нашим данным, в отдалённом послеоперационном периоде дисменорея существенно чаще встречалась у пациенток с аденомиозом (р=0,038). Исследование X. Yangetal [16] показало, что наличие дисменореи и аденомиоза являются независимыми факторами риска послеоперационного рецидива эндометриоидных кист яичников, а возраст на момент операциизащитным фактором. X.Y.…”

unclassified

Long-Term Results After Laparoscopic Interventions in Patients With Concomitant Endometriosis and Adenomyosis

MAHMUDBEYOVA

2023

jecm

View full text Add to dashboard Cite

The aim of the study was to evaluate postoperative outcomes in patients with endometriosis and adenomyosis. The study involved 109 women who had laparoscopic surgery 5 years ago for: chronic pelvic pain -in 29.4%, cystectomy -in 26.6%, hysterectomy -in 22.9%, myomectomy -in 21.1% patients. Stage I endometriosis was observed in 27.5%, stage II -in 26.6%, stage III -in 25.7%, stage IV -in 20.2% of patients. Concomitant adenomyosis occurs in patients with 3rd and 4th degree of severity of endometriosis. The patients were divided into 2 groups: group I -59 patients with endometriosis without adenomyosis; group II -50 patients with endometriosis and adenomyosis. There were no significant differences in average age, body mass index, parity and cases of pelvic pain between the groups. In group II patients, on average, the score on the VAS scale is significantly higher (p=0.045). In group II, dysmenorrhea was higher by 27.1% (p=0.038), dyspareunia -by 48.3% (p=0.042). The chance of developing dysmenorrhea among patients with endometriosis and adenomyosis is 2.3 times higher (OR=0.431, 95% CI 0.193-0.906, p<0.05); dyspareunia is 2.5 times higher (OR=0.407, 95%CI 0.170-0.976, p<0.05). The chance of meeting a woman with pelvic pain is 2.3 times higher among women with endometriosis and adenomyosis (OR=0.426, 95% CI 0.153-1.184, p>0.05). Out of 109 patients, 44.0% of women became pregnant, of which 19.3% had live children. In group II, the number of pregnancies was lower (χ2=3.776, p=0.052). Thus, in the long-term period after laparoscopic intervention, the probability of developing dysmenorrhea, dyspareunia, pelvic pain is high in women with endometriosis and adenomyosis, and the frequency of pregnancy was lower. We consider it appropriate to find such patients under close supervision after surgery.

show abstract